埋め込み型ポート市場調査レポート

Implantable Port Market Research Report

埋め込み型ポート市場調査レポート : 材質別（シリコン、ポリウレタン、チタン）、用途別（化学療法、抗生物質療法、完全静脈栄養、輸血）、挿入方法別（外科的挿入、経皮挿入）、地域別（北米、ヨーロッパ、南米、アジア太平洋、中東、アフリカ）- 2035年までの予測

Implantable Port Market Research Report By Material Type (Silicone, Polyurethane, Titanium), By Application (Chemotherapy, Antibiotic Therapy, Total Parenteral Nutrition, Blood Transfusion), By Insertion Method (Surgical Insertion, Percutaneous Insertion) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

商品番号 : SMB-76800

出版社	Market Research Future
出版年月	2025年3月
ページ数	168
価格タイプ	シングルユーザライセンス
価格	USD 4,950
種別	英文調査報告書

Overview of the Market

According to MRFR research, the Implantable Port Market Size was projected at 2024 USD 3,290.28 Million. The Implantable Port Market Industry is projected to develop at a CAGR (growth rate) of 6.21% over the forecast period (2025 – 2035).

MRFRの調査によると、インプラントポート市場規模は2024年に32億9,028万米ドルに達すると予測されています。インプラントポート市場は、予測期間（2025～2035年）において6.21%のCAGR（年平均成長率）で成長すると予測されています。

Rising prevalence of chronic diseases drive the Implantable Port Market, which in turn increases the need for long-term intravenous access options. Implantable ports are becoming more popular as healthcare practitioners concentrate on improving patient comfort and treatment efficacy. Outpatient and home healthcare environments are expanding, which also drives demand as these facilities need consistent, efficient ways to deliver medication. Improvements in medical technology also guarantee safer, more durable implants, hence driving market expansion even more. Market possibilities include the creation of materials encouraging biocompatibility and reducing infection risk, therefore opening the path for more creative implantable port designs. Increasing patient-centric care focus opens up possibilities for including digital health technologies—such as remote monitoring systems—to enhance patient management. Increasing knowledge among healthcare professionals about the advantages of implantable ports can help to boost market penetration as well, particularly in underdeveloped areas where such technology is still being accepted. Recent trends show a move toward minimally invasive treatments, which would make implantable ports more appealing to both patients and doctors. Manufacturers and doctors working together are more common as they seek to enhance the design and use of these gadgets.

Insights on Market Segments

The worldwide implanted port market has been divided into silicone, polyurethane, and titanium depending on material kind.

The global implantable port market has been divided into chemotherapy, antibiotic therapy, complete parenteral nutrition, and blood transfusion depending on application.

The worldwide implantable port market has been divided into surgical insertion and percutaneous insertion depending on insertion technique. The fastest expanding sector during the forecast period, the surgical insertion segment had the largest market in 2024.

Regional Knowledge

The worldwide implantable port market has been divided into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa depending on the area. In 2024, North America had the biggest market share and is projected to reach USD 2,416.61 million by 2035. On the other hand, Asia-Pacific is expected to expand at the fastest CAGR of 8.32% throughout the forecast period.

With a predicted CAGR of 5.20% throughout the forecast period, the North America implantable port market made USD 1,382.75 million in 2024. North America is also divided into the US and Canada.

With a predicted CAGR of 6.41% throughout the projection period, the Europe implantable port market was USD 972.35 million in 2024. Europe is divided more into Rest of Europe, Russia, Spain, Italy, France, UK, and Germany.

Key Players

Major Companies in the Implantable Port Market Include Easton Medical, Baxter International, Zyga Technology, Terumo, Apex Medical Technologies, Medtronic, Boston Scientific, Cook Medical, AngioDynamics, Kirwan Surgical Products, Smiths Medical, Nitinol Devices Corporation, C R Bard, Stryker, and Halyard Health.

1 EXECUTIVE SUMMARY ………………………………………………………………………………………………… 19

1.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 19

1.2 MARKET ATTRACTIVENESS ANALYSIS …………………………………………………………………………………………….. 20

1.3 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE ………………………………………………………. 21

1.4 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION ……………………………………………………………. 22

1.5 GLOBAL IMPLANTABLE PORT MARKET, BY END USER …………………………………………………………………… 23

1.6 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD ……………………………………………….. 24

1.7 GLOBAL IMPLANTABLE PORT MARKET, BY REGION ……………………………………………………………………….. 25

2 MARKET INTRODUCTION ……………………………………………………………………………………………… 27

2.1 DEFINITION ……………………………………………………………………………………………………………………………………………… 27

2.2 SCOPE OF THE STUDY ……………………………………………………………………………………………………………………………. 27

2.3 RESEARCH OBJECTIVE ………………………………………………………………………………………………………………………….. 27

2.4 MARKET STRUCTURE ……………………………………………………………………………………………………………………………. 27

3 RESEARCH METHODOLOGY ………………………………………………………………………………………… 28

3.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 28

3.2 DATA FLOW ……………………………………………………………………………………………………………………………………………… 30

3.2.1 Data Mining Process ……………………………………………………………………………………………………………………… 30

3.3 PURCHASED DATABASE: ……………………………………………………………………………………………………………………….. 31

3.4 SECONDARY SOURCES: ………………………………………………………………………………………………………………………….. 32

3.4.1 Secondary Research Data Flow: ……………………………………………………………………………………………………….. 33

3.5 PRIMARY RESEARCH: …………………………………………………………………………………………………………………………….. 34

3.5.1 Primary Research Data Flow: ………………………………………………………………………………………………………….. 35

3.5.2 Primary Research: Number of Interviews conducted ……………………………………………………………………………. 36

3.5.3 Primary Research: Regional Coverage ………………………………………………………………………………………………. 36

3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ………………………………………………………………………………. 37

3.6.1 Revenue Analysis Approach ……………………………………………………………………………………………………………. 37

3.7 DATA FORECASTING………………………………………………………………………………………………………………………………. 38

3.7.1 Data forecasting Type ……………………………………………………………………………………………………………………. 38

3.8 DATA MODELING …………………………………………………………………………………………………………………………………….. 39

3.8.1 Microeconomic Factor Analysis: ………………………………………………………………………………………………………. 39

3.8.2 Data modeling: …………………………………………………………………………………………………………………………….. 40

3.9 TEAMS AND ANALYST CONTRIBUTION …………………………………………………………………………………………….. 42

4 MARKET DYNAMICS …………………………………………………………………………………………………….. 44

4.1 INTRODUCTION ……………………………………………………………………………………………………………………………………….. 44

4.2 DRIVERS ……………………………………………………………………………………………………………………………………………………. 44

4.2.1 Increasing Incidences of Chronic Diseases across the globe………………………………………………………………….. 44

4.2.2 Technological Advancements ………………………………………………………………………………………………………….. 45

4.2.3 Better Healthcare Access ……………………………………………………………………………………………………………….. 46

4.3 RESTRAINTS ……………………………………………………………………………………………………………………………………………. 47

4.3.1 High Cost of Implantation ………………………………………………………………………………………………………………. 47

4.3.2 Surgical Risks ………………………………………………………………………………………………………………………………. 47

4.4 OPPORTUNITY …………………………………………………………………………………………………………………………………………. 48

4.4.1 Expansion in Emerging Markets ……………………………………………………………………………………………………….. 48

4.4.2 Growing Aging Population ………………………………………………………………………………………………………………. 48

5 MARKET FACTOR ANALYSIS ………………………………………………………………………………………… 49

5.1 VALUE CHAIN ANALYSIS ……………………………………………………………………………………………………………………… 49

5.1.1 R&D …………………………………………………………………………………………………………………………………………… 49

5.1.2 Manufacturing ……………………………………………………………………………………………………………………………… 49

5.1.3 Marketing and Distribution & Channel ……………………………………………………………………………………………….. 49

5.1.4 Post-market Surveillance ……………………………………………………………………………………………………………….. 50

5.2 PORTER’S FIVE FORCES MODEL …………………………………………………………………………………………………………… 50

5.2.1 Threat of New Entrants ………………………………………………………………………………………………………………….. 51

5.2.2 Bargaining Power of Suppliers …………………………………………………………………………………………………………. 51

5.2.3 Threat of Substitutes …………………………………………………………………………………………………………………….. 52

5.2.4 Bargaining Power of Buyers ……………………………………………………………………………………………………………. 52

5.2.5 Intensity of Rivalry ………………………………………………………………………………………………………………………… 52

5.3 IMPACT OF COVID-19 ON THE GLOBAL IMPLANTABLE PORT MARKET ……………………………………….. 53

6 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE …………………………………………. 55

6.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 55

6.2 SILICONE …………………………………………………………………………………………………………………………………………………… 57

6.3 POLYURETHANE …………………………………………………………………………………………………………………………………….. 58

6.4 TITANIUM ………………………………………………………………………………………………………………………………………………… 58

7 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION ……………………………………………… 59

7.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 59

7.2 CHEMOTHERAPY ……………………………………………………………………………………………………………………………………. 61

7.3 ANTIBIOTIC THERAPY …………………………………………………………………………………………………………………………… 62

7.4 TOTAL PARENTERAL NUTRITION ………………………………………………………………………………………………………. 62

7.5 BLOOD TRANSFUSION ……………………………………………………………………………………………………………………………. 63

8 GLOBAL IMPLANTABLE PORT MARKET, BY END USER ………………………………………………….. 64

8.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 64

8.2 HOSPITALS ………………………………………………………………………………………………………………………………………………. 66

8.3 AMBULATORY SURGICAL CENTERS ……………………………………………………………………………………………………. 67

8.4 SPECIALIZED CLINICS …………………………………………………………………………………………………………………………….. 67

9 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD ………………………………….. 68

9.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 68

9.2 SURGICAL INSERTION ……………………………………………………………………………………………………………………………. 70

9.3 PERCUTANEOUS INSERTION ………………………………………………………………………………………………………………… 71

10 GLOBAL IMPLANTABLE PORT MARKET, BY REGION ……………………………………………………… 72

10.1 OVERVIEW ……………………………………………………………………………………………………………………………………………….. 72

10.2 NORTH AMERICA ……………………………………………………………………………………………………………………………………. 74

10.2.1 US……………………………………………………………………………………………………………………………………………… 77

10.2.2 CANADA …………………………………………………………………………………………………………………………………….. 78

10.3 EUROPE …………………………………………………………………………………………………………………………………………………….. 80

10.3.1 GERMANY …………………………………………………………………………………………………………………………………… 83

10.3.2 FRANCE ……………………………………………………………………………………………………………………………………… 84

10.3.3 UK …………………………………………………………………………………………………………………………………………….. 86

10.3.4 ITALY …………………………………………………………………………………………………………………………………………. 88

10.3.5 SPAIN ………………………………………………………………………………………………………………………………………… 90

10.3.6 RUSSIA ………………………………………………………………………………………………………………………………………. 92

10.3.7 REST OF EUROPE ………………………………………………………………………………………………………………………….. 94

10.4 ASIA-PACIFIC …………………………………………………………………………………………………………………………………………… 96

10.4.1 CHINA ………………………………………………………………………………………………………………………………………… 99

10.4.2 INDIA …………………………………………………………………………………………………………………………………………. 100

10.4.3 JAPAN ……………………………………………………………………………………………………………………………………….. 102

10.4.4 SOUTH KOREA ……………………………………………………………………………………………………………………………… 103

10.4.5 MALAYSIA ………………………………………………………………………………………………………………………………….. 104

10.4.6 THAILAND …………………………………………………………………………………………………………………………………… 106

10.4.7 INDONESIA ………………………………………………………………………………………………………………………………….. 107

10.4.8 REST OF ASIA-PACIFIC ………………………………………………………………………………………………………………….. 108

10.5 SOUTH AMERICA ……………………………………………………………………………………………………………………………………. 110

10.5.1 BRAZIL ……………………………………………………………………………………………………………………………………….. 113

10.5.2 MEXICO ……………………………………………………………………………………………………………………………………… 114

10.5.3 ARGENTINA ………………………………………………………………………………………………………………………………… 116

10.5.4 REST OF SOUTH AMERICA ……………………………………………………………………………………………………………… 117

10.6 MIDDLE EAST AND AFRICA …………………………………………………………………………………………………………………… 119

10.6.1 GCC COUNTRIES…………………………………………………………………………………………………………………………… 122

10.6.2 SOUTH AFRICA …………………………………………………………………………………………………………………………….. 123

10.6.3 REST OF MIDDLE EAST AND AFRICA …………………………………………………………………………………………………. 125

11 COMPETITIVE LANDSCAPE ………………………………………………………………………………………….. 128

11.1 INTRODUCTION ……………………………………………………………………………………………………………………………………….. 128

11.2 COMPANY MARKET SHARE ANALYSIS, 2024 (VALUE) ……………………………………………………………………. 128

11.3 COMPETITOR DASHBOARD……………………………………………………………………………………………………………………. 129

11.4 PUBLIC PLAYERS STOCK SUMMARY ………………………………………………………………………………………………….. 130

11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL …………………………………………………………………… 130

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ……………………………………………………………………………….. 130

11.6.1 DONATION ………………………………………………………………………………………………………………………………….. 130

11.6.2 AGREEMENT ……………………………………………………………………………………………………………………………….. 131

12 COMPANY PROFILES …………………………………………………………………………………………………… 132

12.1 ANGIODYNAMICS, INC. …………………………………………………………………………………………………………………………… 132

12.1.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 132

12.1.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 133

12.1.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 134

12.1.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 135

12.1.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 136

12.1.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 136

12.2 B. BRAUN MELSUNGEN AG …………………………………………………………………………………………………………………… 137

12.2.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 137

12.2.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 138

12.2.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 138

12.2.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 139

12.2.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 139

12.2.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 139

12.3 BECTON, DICKINSON AND COMPANY (BD) …………………………………………………………………………………………. 140

12.3.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 140

12.3.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 141

12.3.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 141

12.3.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 142

12.3.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 142

12.3.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 143

12.4 COOK MEDICAL LLC ………………………………………………………………………………………………………………………………… 144

12.4.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 144

12.4.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 144

12.4.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 145

12.4.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 145

12.4.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 145

12.4.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 146

12.5 DISTRICLASS MEDICAL SA ……………………………………………………………………………………………………………………. 147

12.5.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 147

12.5.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 147

12.5.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 147

12.5.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 147

12.5.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 148

12.5.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 148

12.6 VYGON ………………………………………………………………………………………………………………………………………………………. 149

12.6.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 149

12.6.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 150

12.6.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 150

12.6.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 151

12.6.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 151

12.6.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 152

12.7 SILMAG AG……………………………………………………………………………………………………………………………………………….. 153

12.7.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 153

12.7.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 153

12.7.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 153

12.7.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 153

12.7.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 154

12.7.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 154

12.8 POLY MEDICURE LTD ……………………………………………………………………………………………………………………………… 155

12.8.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 155

12.8.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 156

12.8.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 156

12.8.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 158

12.8.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 158

12.8.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 159

12.9 PAKUMEDMEDICAL PRODUCTS GMBH ………………………………………………………………………………………………. 160

12.9.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 160

12.9.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 160

12.9.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 161

12.9.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 161

12.9.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 162

12.9.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 162

12.10 SOPHYSA ………………………………………………………………………………………………………………………………………………….. 163

12.10.1 COMPANY OVERVIEW ……………………………………………………………………………………………………………………. 163

12.10.2 FINANCIAL OVERVIEW …………………………………………………………………………………………………………………… 163

12.10.3 PRODUCTS/SOLUTIONS/SERVICES OFFERED ……………………………………………………………………………………… 164

12.10.4 KEY DEVELOPMENTS …………………………………………………………………………………………………………………….. 164

12.10.5 SWOT ANALYSIS ………………………………………………………………………………………………………………………….. 164

12.10.6 KEY STRATEGIES ………………………………………………………………………………………………………………………….. 165

13 DATA CITATIONS …………………………………………………………………………………………………………. 166

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 40

TABLE 2 GLOBAL IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 56

TABLE 3 GLOBAL IMPLANTABLE PORT MARKET, FOR SILICONE, BY REGION, 2019–2035 (USD MILLION) 57

TABLE 4 GLOBAL IMPLANTABLE PORT MARKET, FOR POLYURETHANE, BY REGION, 2019–2035 (USD MILLION) 58

TABLE 5 GLOBAL IMPLANTABLE PORT MARKET, FOR TITANIUM, BY REGION, 2019–2035 (USD MILLION) 58

TABLE 6 GLOBAL IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 60

TABLE 7 GLOBAL IMPLANTABLE PORT MARKET, FOR CHEMOTHERAPY, BY REGION, 2019–2035 (USD MILLION) 61

TABLE 8 GLOBAL IMPLANTABLE PORT MARKET, FOR ANTIBIOTIC THERAPY, BY REGION, 2019–2035 (USD MILLION) 62

TABLE 9 GLOBAL IMPLANTABLE PORT MARKET, FOR TOTAL PARENTERAL NUTRITION, BY REGION, 2019–2035 (USD MILLION) 62

TABLE 10 GLOBAL IMPLANTABLE PORT MARKET, FOR BLOOD TRANSFUSION, BY REGION, 2019–2035 (USD MILLION) 63

TABLE 11 GLOBAL IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 65

TABLE 12 GLOBAL IMPLANTABLE PORT MARKET, FOR HOSPITALS, BY REGION, 2019–2035 (USD MILLION) 66

TABLE 13 GLOBAL IMPLANTABLE PORT MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019–2035 (USD MILLION) 67

TABLE 14 GLOBAL IMPLANTABLE PORT MARKET, FOR SPECIALIZED CLINICS, BY REGION, 2019–2035 (USD MILLION) 67

TABLE 15 GLOBAL IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 69

TABLE 16 GLOBAL IMPLANTABLE PORT MARKET, FOR SURGICAL INSERTION, BY REGION, 2019–2035 (USD MILLION) 70

TABLE 17 GLOBAL IMPLANTABLE PORT MARKET, FOR PERCUTANEOUS INSERTION, BY REGION, 2019–2035 (USD MILLION) 71

TABLE 18 GLOBAL IMPLANTABLE PORT MARKET, BY REGION, 2019–2035 (USD MILLION) 72

TABLE 19 NORTH AMERICA: IMPLANTABLE PORT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 75

TABLE 20 NORTH AMERICA IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 75

TABLE 21 NORTH AMERICA IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 76

TABLE 22 NORTH AMERICA IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 76

TABLE 23 NORTH AMERICA IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 76

TABLE 24 US IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 77

TABLE 25 US IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 77

TABLE 26 US IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 77

TABLE 27 US IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 78

TABLE 28 CANADA IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 78

TABLE 29 CANADA IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 78

TABLE 30 CANADA IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 79

TABLE 31 CANADA IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 79

TABLE 32 EUROPE IMPLANTABLE PORT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 80

TABLE 33 EUROPE: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 82

TABLE 34 EUROPE: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 82

TABLE 35 EUROPE: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 82

TABLE 36 EUROPE: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 83

TABLE 37 GERMANY: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 83

TABLE 38 GERMANY: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83

TABLE 39 GERMANY: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 84

TABLE 40 GERMANY: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 84

TABLE 44 FRANCE: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 85

TABLE 45 UK: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 86

TABLE 46 UK: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 86

TABLE 47 UK: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 87

TABLE 48 UK: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 87

TABLE 49 ITALY: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 88

TABLE 50 ITALY: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 88

TABLE 51 ITALY: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 89

TABLE 52 ITALY: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 89

TABLE 53 SPAIN: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 90

TABLE 54 SPAIN: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 90

TABLE 55 SPAIN: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 91

TABLE 56 SPAIN: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 91

TABLE 57 RUSSIA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 92

TABLE 58 RUSSIA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 92

TABLE 59 RUSSIA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 93

TABLE 60 RUSSIA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 93

TABLE 61 REST OF EUROPE: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 94

TABLE 62 REST OF EUROPE: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 94

TABLE 63 REST OF EUROPE: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 95

TABLE 64 REST OF EUROPE: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 95

TABLE 65 ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 97

TABLE 66 ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 98

TABLE 67 ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 98

TABLE 68 ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 98

TABLE 69 ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 99

TABLE 70 CHINA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 99

TABLE 71 CHINA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 99

TABLE 72 CHINA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 100

TABLE 73 CHINA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 100

TABLE 74 INDIA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 100

TABLE 75 INDIA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 101

TABLE 76 INDIA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 101

TABLE 77 INDIA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 101

TABLE 78 JAPAN: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 102

TABLE 79 JAPAN: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 102

TABLE 80 JAPAN: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 102

TABLE 81 JAPAN: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 103

TABLE 82 SOUTH KOREA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 103

TABLE 83 SOUTH KOREA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 103

TABLE 84 SOUTH KOREA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 104

TABLE 85 SOUTH KOREA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 104

TABLE 86 MALAYSIA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 104

TABLE 87 MALAYSIA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 105

TABLE 88 MALAYSIA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 105

TABLE 89 MALAYSIA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 105

TABLE 90 THAILAND: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 106

TABLE 91 THAILAND: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 106

TABLE 92 THAILAND: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 106

TABLE 93 THAILAND: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 107

TABLE 94 INDONESIA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 107

TABLE 95 INDONESIA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 107

TABLE 96 INDONESIA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 108

TABLE 97 INDONESIA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 108

TABLE 98 REST OF ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 108

TABLE 99 REST OF ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109

TABLE 100 REST OF ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 109

TABLE 101 REST OF ASIA-PACIFIC: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 109

TABLE 102 SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 111

TABLE 103 SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 112

TABLE 104 SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 112

TABLE 105 SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 112

TABLE 106 SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 113

TABLE 107 BRAZIL: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 113

TABLE 108 BRAZIL: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 113

TABLE 109 BRAZIL: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 114

TABLE 110 BRAZIL: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 114

TABLE 111 MEXICO: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 114

TABLE 112 MEXICO: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115

TABLE 113 MEXICO: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 115

TABLE 114 MEXICO: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 115

TABLE 115 ARGENTINA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 116

TABLE 116 ARGENTINA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116

TABLE 117 ARGENTINA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 116

TABLE 118 ARGENTINA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 117

TABLE 119 REST OF SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 117

TABLE 120 REST OF SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 117

TABLE 121 REST OF SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 118

TABLE 122 REST OF SOUTH AMERICA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 118

TABLE 123 MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 120

TABLE 124 MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 121

TABLE 125 MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 121

TABLE 126 MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 121

TABLE 127 MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 122

TABLE 128 GCC COUNTRIES: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 122

TABLE 129 GCC COUNTRIES: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 122

TABLE 130 GCC COUNTRIES: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 123

TABLE 131 GCC COUNTRIES: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 123

TABLE 132 SOUTH AFRICA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 123

TABLE 133 SOUTH AFRICA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 124

TABLE 134 SOUTH AFRICA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 124

TABLE 135 SOUTH AFRICA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 124

TABLE 136 REST OF MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY MATERIAL TYPE, 2019–2035 (USD MILLION) 125

TABLE 137 REST OF MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 125

TABLE 138 REST OF MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY END USER, 2019–2035 (USD MILLION) 126

TABLE 139 REST OF MIDDLE EAST AND AFRICA: IMPLANTABLE PORT MARKET, BY INSERTION METHOD, 2019–2035 (USD MILLION) 126

TABLE 140 DONATION 130

TABLE 141 AGREEMENT 131

TABLE 142 ANGIODYNAMICS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 134

TABLE 143 ANGIODYNAMICS, INC.: KEY DEVELOPMENTS 135

TABLE 144 B. BRAUN MELSUNGEN AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 138

TABLE 145 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS/SOLUTIONS/SERVICES OFFERED 141

TABLE 146 COOK MEDICAL LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 145

TABLE 147 DISTRICLASS MEDICAL SA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 147

TABLE 148 VYGON SA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 150

TABLE 149 VYGON SA: KEY DEVELOPMENTS 151

TABLE 150 SILMAG AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 153

TABLE 151 POLY MEDICURE LTD: PRODUCTS/SOLUTIONS/SERVICES OFFERED 156

TABLE 152 PAKUMEDMEDICAL PRODUCTS GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED 161

TABLE 153 SOPHYSA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 164